A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors

Introduction: Denosumab (Xgeva®) is a standard treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM). This trial was designed to assess the equivalence of LY01011 to denosumab in terms of efficacy and safety. Materials and methods: Eligible patients wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Mingchuan Zhao, Xichun Hu, Pengpeng Zhuang, Aiping Zeng, Yan Yu, Zhendong Chen, Hongmei Sun, Weihua Yang, Lili Sheng, Peijian Peng, Jingfen Wang, Tienan Yi, Minghong Bi, Huaqiu Shi, Mingli Ni, Xiumei Dai, Changlu Hu, Hongjie Xu, Dongqing Lv, Qingshan Li, Kaijian Lei, Xia Yuan, Ou Jiang, Xicheng Wang, Baihui Hu, Zhe Hou, Zhaoping Su, Song Zheng, Ming Zhou, Changlin Dou
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Journal of Bone Oncology
Subjects:
Bone metastasis
Breast cancer
Denosumab
LY01011
Receptor activator of NF-κB ligand (RANKL)
Urinary N-telopeptide to urinary creatinine (uNTx/uCr) ratio
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137425000028
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2212137425000028

Similar Items